Dysbindin gene (DTNBP1) in major depression: Association with clinical response to selective serotonin reuptake inhibitors

Pharmacogenetics and Genomics

Volumn 19, Issue 2, 2009, Pages 121-128

  Arias, Bárbara ^a   Serretti, Alessandro ^d   Mandelli, Laura ^d   Gastó, Cristóbal ^b,c   Catalań, Rosa ^b,c   De Ronchi, Diana ^d   Fañanás, Lourdes ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

^b Hospital Clínic i Provincial de Barcelona   (Italy)

^c INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

^d UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Clinical response; Dysbindin gene; Major depression; Pharmacogenetics; Selective serotonin reuptake inhibitors

Indexed keywords

CITALOPRAM; DYSBINDIN; SEROTONIN UPTAKE INHIBITOR;

ADULT; ALLELE; ARTICLE; CONTROLLED STUDY; DEVICE; DTNBP1 GENE; FEMALE; GENE; GENE LINKAGE DISEQUILIBRIUM; GENETIC PROCEDURES; GENOTYPE; HAMILTON SCALE; HAPLOTYPE; HUMAN; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; PHARMACOGENETICS; PRIORITY JOURNAL; REMISSION; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT OUTCOME;

EID: 59549097542     PISSN: 17446872     EISSN: 17446880     Source Type: Journal    
DOI: 10.1097/FPC.0b013e32831ebb4b     Document Type: Article

References (63)

1. Bierut LJ, Heath AC, Bucholz KK, Dinwiddie SH, Madden PA, Statham DJ, et al. Major depressive disorder in a community-based twin sample: are there different genetic and environmental contributions for men and women? Arch Gen Psychiatry 1999; 56:557-563.
2. Hamet P, Tremblay J. Genetics and genomics of depression. Metabolism 2005; 54:10-15.
3. Caspi A, Sugden K, Moffitt TE, Taylor A, Craig IW, Harrington H, et al. Influence of life stress on depression: moderation by a polymorphism in the 5-HTT gene. Science 2003; 301:386-389.
4. Martin RM, Hilton SR, Kerry SM, Richards NM. General practitioners' perceptions of the tolerability of antidepressant drugs: a comparison of selective serotonin reuptake inhibitors and tricyclic antidepressants. Br Med J 1997; 314:646-651.
5. Stoltenberg SF, Burmeister M. Recent progress in psychiatric genetics - some hope but no hype. Hum Mol Genet 2000; 9:927-935.
6. D'Sa C, Duman RS. Antidepressants and neuroplasticity. Bipolar Disord 2002; 4:183-194.
7. Benson MA, Newey SE, Martin-Rendon E, Hawkes R, Blake DJ. Dysbindin, a novel coiled-coil-containing protein that interacts with the dystrobrevins in muscle and brain. J Biol Chem 2001; 276:24232-24241.
8. Straub RE, Jiang Y, MacLean CJ, Ma Y, Webb BT, Myakishev MV, et al. Genetic variation in the 6p22.3 gene DTNBP1, the human ortholog of the mouse dysbindin gene, is associated with schizophrenia. Am J Hum Genet 2002; 71:337-348.
9. Numakawa T, Yagasaki Y, Ishimoto T, Okada T, Suzuki T, Iwata N, et al. Evidence of novel neuronal functions of dysbindin, a susceptibility gene for schizophrenia. Hum Mol Genet 2004; 13:2699-2708.
10. Knuesel I, Mastrocola M, Zuellig RA, Bomhauser B, Schaub MC, Fritschy JM. Short communication: altered synaptic clustering of GABAA receptors in mice lacking dystrophin (mdx mice). Eur J Neurosci 1999; 11:4457-4462.
11. Talbot K, Eidem WL, Tinsley CL, Benson MA, Thompson EW, Smith RJ, et al. Dysbindin-1 is reduced in intrinsic, glutamatergic terminals of the hippocampal formation in schizophrenia. J Clin Invest 2004; 113:1353-1363.
12. Yoshimizu T, Shimazaki T, Ito A, Chaki S. An mGluR2/3 antagonist, MGS0039, exerts antidepressant and anxiolytic effects in behavioral models in rats. Psychopharmacology (Berl) 2006; 186:587-593.
13. Yagasaki Y, Numakawa T, Kumamaru E, Hayashi T, Su TP, Kunugi H. Chronic antidepressants potentiate via sigma-1 receptors the brain-derived neurotrophic factor-induced signaling for glutamate release. J Biol Chem 2006; 281:12941-12949.
14. Williams NM, O'Donovan MC, Owen MJ. Is the dysbindin gene (DTNBP1) a susceptibility gene for schizophrenia? Schizophr Bull 2005; 31:800-805.
15. Li DW, He L. Association study between the dystrobrevin binding protein 1 gene (DTNBP1) and schizophrenia: a meta-analysis. Schizophrenia Research 2007; 96:112-118.
16. Duan JB, Martinez M, Sanders AR, Hou CP, Burrell GJ, Krasner AJ, et al. DTNBP1 (dystrobrevin binding protein 1) and schizophrenia: association evidence in the 3′ end of the gene. Human Heredity 2007; 64:97-106.
17. Vilella E, Costas J, Sanjuan J, Guitart M, De Diego Y, Carracedo A, et al. Association of schizophrenia with DTNBP1 but not with DAO, DAOA, NRG1 and RGS4 nor their genetic interaction. J Psychiatr Res 2008; 42:278-288.
18. Corvin A, Donohoe G, Mangle JM, Schwaiger S, Morris D, Gill M. A dysbindin risk haplotype associated with less severe manic-type symptoms in psychosis. Neurosci Lett 2008; 431:146-149.
19. Fallin MD, Lasseter VK, Avramopoulos D, Nicodemus KK, Wolyniec PS, McGrath JA, et al. Bipolar I disorder and schizophrenia: a 440-single-nucleotide polymorphism screen of 64 candidate genes among Ashkenazi Jewish case-parent trios. Am J Hum Genet 2005; 77:918-936.
20. Raybould R, Green EK, MacGregor S, Gordon-Smith K, Heron J, Hyde S, et al. Bipolar disorder and polymorphisms in the dysbindin gene (DTNBP1). Biol Psychiatry 2005; 57:696-701.
21. Breen G, Prata D, Osborne S, Munro J, Sinclair M, Li T, et al. Association of the dysbindin gene with bipolar affective disorder. Am J Psychiatry 2006; 163:1636-1638.
22. Craddock N, O'Donovan MC, Owen MJ. Genes for schizophrenia and bipolar disorder? Implications for psychiatric nosology. Schizophr Bull 2006; 32:9-16.
23. Joo EJ, Lee KY, Jeong SH, Chang JS, Ahn YM, Koo YJ, et al. Dysbindin gene variants are associated with bipolar I disorder in a Korean population. Neurosci Lett 2007; 418:272-275.
24. Pae CU, Serretti A, Mandelli L, De Ronchi D, Patkar AA, Jun TY, et al. Dysbindin associated with selective serotonin reuptake inhibitor antidepressant efficacy. Pharmacogenetics and Genomics 2007; 17:69-75.
25. Zill P, Baghai TC, Engel R, Zwanzger P, Schule C, Eser D, et al. The dysbindin gene in major depression: an association study. Am J Med Genet B Neuropsychiatr Genet 2004; 129:55-58.
26. Kim JJ, Mandelli L, Pae CU, De Ronchi D, Jun TY, Lee C, et al. Is there protective haplotype of dysbindin gene (DTNBP1) 3 polymorphisms for major depressive disorder. Prog Neuropsychopharmacol Biol Psychiatry 2008; 32:375-379.
27. Arias B, Catalan R, Gasto C, Gutierrez B, Fananas L. 5-HTTLPR polymorphism of the serotonin transporter gene predicts non-remission in major depression patients treated with citalopram in a 12-weeks follow up study. J Clin Psychopharmacol 2003; 23:563-567.
28. Lee MS, Lee HY, Lee HJ, Ryu SH. Serotonin transporter promoter gene polymorphism and long-term outcome of antidepressant treatment. Psychiatr Genet 2004; 14:111-115.
29. Binder EB, Holsboer F. Pharmacogenomics and antidepressant drugs. Ann Med 2006; 38:82-94.
30. Spitzer RLWJ, Gibbon M, First MEB. Structured clinical interview for DSM-III-R. Washington DC: American Psychiatric Press; 1990.
31. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960; 23:56-62.
32. Goldberg DP, Hillier VF. Scaled version of the general health questionnaire. Psychol Med 1979; 9:139-145.
33. Baumann P, Nil R, Souche A, Montaldi S, Baettig D, Lambert S, et al. A double-blind, placebo-controlled study of citalopram with and without lithium in the treatment of therapy-resistant depressive patients: a clinical, pharmacokinetic, and pharmacogenetic investigation. J Clin Psychopharmacol 1996; 16:307-314.
34. Frank E, Prien RF, Jarrett RB, Keller MB, Kupfer DJ, Lavori PW, et al. Conceptualization and rationale for consensus definitions of terms in major depressive disorder. Remission, recovery, relapse, and recurrence. Arch Gen Psychiatry 1991; 48:851-855.
35. Olesen OV, Linnet K. Simplified high-performance liquid chromatographic method for the determination of citalopram and desmethylcitalopram in serum without interference from commonly used psychotropic drugs and their metabolites. J Chromatogr B Biomed Appl 1996; 675:83-88.
36. Lingjaerde O, Ahlfors UG, Bech P, Dencker SJ, Eigen K. The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients. Acta Psychiatr Scand Suppl 1987; 334:1-100.
37. Barrett JC, Fry B, Mailer J, Daly MJ. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 2005; 21(2):263-265.
38. Barret O, Carpenter TA, Clark JC, Ansorge RE, Fryer TD. Monte Carlo simulation and scatter correction of the GE advance PET scanner with SimSET and Geant4. Phys Med Biol 2005; 50:4823-4840.
39. Ihaka R, Gentleman R. Statistics Department of the University of Auckland, New Zealand. Free software, http://www.r-project.org
40. Cohen J. Statistical power analysis for the behavioral sciences. New Jersey: Hillsdale; 1988.
41. Tsuang M, Faraone S. The genetics of mood disorders. Baltimore: The Johns Hopkins University Press; 1990.
42. Hasler G, Drevets WC, Manji HK, Charney DS. Discovering endophenotypes for major depression. Neuropsychopharmacology 2004; 29:1765-1781.
43. Mueller JC, Lohmussaar E, Magi R, Remm M, Bettecken T, Lichtner P, et al. Linkage disequilibrium patterns and tagSNP transferability among European populations. Am J Hum Genet 2005; 76:387-398.
44. Pittenger C, Sanacora G, Krystal JH. The NMDA receptor as a therapeutic target in major depressive disorder. CNS Neurol Disord Drug Targets 2007; 6:101-115.
45. Cameron HA, McEwen BS, Gould E. Regulation of adult neurogenesis by excitatory input and NMDA receptor activation in the dentate gyrus. J Neurosci 1995; 15:4687-4692.
46. Magarinos AM, McEwen BS. Stress-induced atrophy of apical dendrites of hippocampal CA3c neurons: involvement of glucocorticoid secretion and excitatory amino acid receptors. Neuroscience 1995; 69:89-98.
47. Kalo M, Ikenaga Y, Wakeno M, Okugawa G, Nobuhara K, Fukuda T, et al. Controlled clinical comparison of paroxetine and fluvoxamine considering the serotonin transporter promoter polymorphism, Int Clin Psychopharmacol 2005; 20:151-156.
48. Pollock BG, Ferrell RE, Mulsant BH, Mazumdar S, Miller M, Sweet RA, et al. Allelic variation in the serotonin transporter promoter affects onset of paroxetine treatment response in late-life depression. Neuropsychopharmacology 2000; 23:587-590.
49. Zanardi R, Benedetti F, Di Bella D, Catalano M, Smeraldi E. Efficacy of paroxetine in depression is influenced by a functional polymorphism within the promoter of the serotonin transporter gene. J Clin Psychopharmacol 2000; 20:105-107.
50. Keller MB. Remission versus response: the new gold standard of antidepressant care. J Clin Psychiatry 2004; 65 (Suppl 4):53-59.
51. Serretti A, Calati R, Mandelli L, De Ronchi D. Serotonin transporter gene variants and behavior: a comprehensive review. Curr Drug Targets 2006; 7:1659-1669.
52. DeRosse P, Funke B, Burdick KE, Lencz T, Ekholm JM, Kane JM, et al. Dysbindin genotype and negative symptoms in schizophrenia. Am J Psychiatry 2006; 163:532-534.
53. Tochigi M, Zhang X, Ohashi J, Hibino H, Otowa T, Rogers M, et al. Association study of the dysbindin (DTNBP1) gene in schizophrenia from the Japanese population. Neurosci Res 2006; 56:154-158.
54. Fanous A, Gardner CO, Prescott CA, Cancro R, Kendler KS. Neuroticism, major depression and gender: a population-based twin study. Psychol Med 2002; 32:719-728.
55. Schwab SG, Knapp M, Mondabon S, Hallmayer J, Borrmann-Hassenbach M, Albus M, et al. Support for association of schizophrenia with genetic variation in the 6p22.3 gene, dysbindin, in sib-pair families with linkage and in an additional sample of triad families. Am J Hum Genet 2003; 72:185-190.
56. Van Den Bogaert A, Schumacher J, Schulze TG, Otte AC, Ohlraun S, Kovalenko S, et al. The DTNBP1 (dysbindin) gene contributes to schizophrenia, depending on family history of the disease. Am J Hum Genet 2003; 73:1438-1443.
57. Kendler KS. 'A gene for...': the naure of gene action in psychiatric disorders. Am J Psychiatry 2005; 162:1243-1252.
58. Kendler KS. Reflections on the relationship between psychiatric genetics and psychiatric nosology. Am J Psychiatry 2006; 163:1138-1146.
59. Fan JB, Sklar P. Meta-analysis reveals association between serotonin transporter gene STin2 VNTR polymorphism and schizophrenia. Mol Psychiatry 2005; 10:928-938.
60. Lasky-Su JA, Faraone SV, Glatt SJ, Tsuang MT. Meta-analysis of the association between two polymorphisms in the serotonin transporter gene and affective disorders. Am J Med Genet B Neuropsychiatry Genet 2005; 133:110-115.
61. Lopez Leon S, Croes EA, Sayed-Tabatabaei FA, Claes S, Van Broeckhoven C, van Duijn CM. The dopamine D4 receptor gene 48-base-pair-repeat polymorphism and mood disorders: a meta-analysis. Biol Psychiatry 2005; 57:999-1003.
62. Bray NJ, Preece A, Williams NM, Moskvina V, Buckland PR, Owen MJ, et al. Haplotypes at the dystrobrevin binding protein 1 (DTNBP1) gene locus mediate risk for schizophrenia through reduced DTNBP1 expression. Hum Mol Genet 2005; 14:1947-1954.
63. Cavalli Sforza L. The history and geography of human genes. Princeton, New Jersey, USA: Princeton University Press; 1994.